

Kosuke Kaji

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3268223/publications.pdf>

Version: 2024-02-01

94
papers

1,596
citations

361296

20
h-index

377752

34
g-index

96
all docs

96
docs citations

96
times ranked

2202
citing authors

#	ARTICLE	IF	CITATIONS
1	Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake. <i>International Journal of Cancer</i> , 2018, 142, 1712-1722.	2.3	136
2	Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats. <i>Journal of Gastroenterology</i> , 2014, 49, 481-491.	2.3	107
3	Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity. <i>World Journal of Gastroenterology</i> , 2017, 23, 8355-8366.	1.4	85
4	Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2009, 51, 315-321.	1.8	84
5	Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model. <i>Molecular Medicine Reports</i> , 2015, 11, 1693-1700.	1.1	62
6	Sulforaphane ameliorates ethanol plus carbon tetrachloride-induced liver fibrosis in mice through the Nrf2-mediated antioxidant response and acetaldehyde metabolism with inhibition of the LPS/TLR4 signaling pathway. <i>Journal of Nutritional Biochemistry</i> , 2021, 89, 108573.	1.9	58
7	Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis. <i>Hepatology Research</i> , 2020, 50, 840-852.	1.8	46
8	Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 300, G1094-G1104.	1.6	44
9	Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities. <i>Oncology Reports</i> , 2009, 22, 355-60.	1.2	41
10	Attenuation of insulin-resistance-based hepatocarcinogenesis and angiogenesis by combined treatment with branched-chain amino acids and angiotensin-converting enzyme inhibitor in obese diabetic rats. <i>Journal of Gastroenterology</i> , 2010, 45, 443-450.	2.3	33
11	Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients. <i>Antibiotics</i> , 2020, 9, 145.	1.5	33
12	Angiotensin receptor blockade attenuates cholangiocarcinoma cell growth by inhibiting the oncogenic activity of Yes-associated protein. <i>Cancer Letters</i> , 2018, 434, 120-129.	3.2	31
13	Angiotensin-II and vascular endothelial growth factor interaction plays an important role in rat liver fibrosis development. <i>Hepatology Research</i> , 2006, 36, 124-129.	1.8	30
14	Predictive parameter of tolvaptan effectiveness in cirrhotic ascites. <i>Hepatology Research</i> , 2017, 47, 854-861.	1.8	30
15	Eosinophilic cholecystitis along with pericarditis caused by <i>Ascaris lumbricoides</i> : A case report. <i>World Journal of Gastroenterology</i> , 2007, 13, 3760.	1.4	28
16	von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and C. <i>United European Gastroenterology Journal</i> , 2018, 6, 1401-1409.	1.6	27
17	Relationship between hepatic progenitor cell-mediated liver regeneration and non-parenchymal cells. <i>Hepatology Research</i> , 2016, 46, 1187-1193.	1.8	26
18	Impact of insulin resistance on the progression of chronic liver diseases. <i>International Journal of Molecular Medicine</i> , 2008, 22, 801-8.	1.8	26

#	ARTICLE	IF	CITATIONS
19	Combining probiotics and an angiotensin-II type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis. <i>Hepatology Research</i> , 2019, 49, 284-295.	1.8	25
20	Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis. <i>Hepatology Research</i> , 2017, 47, 1317-1328.	1.8	22
21	Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5589.	1.8	21
22	Dual blockade of angiotensin-II and aldosterone suppresses the progression of a non-diabetic rat model of steatohepatitis. <i>Hepatology Research</i> , 2013, 43, 765-774.	1.8	20
23	VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2019, 19, 167.	0.8	20
24	Selective aldosterone blocker, eplerenone, attenuates hepatocellular carcinoma growth and angiogenesis in mice. <i>Hepatology Research</i> , 2010, 40, 540-549.	1.8	19
25	Management of refractory cirrhotic ascites: challenges and solutions. <i>Hepatic Medicine: Evidence and Research</i> , 2018, Volume 10, 55-71.	0.9	18
26	Oral administration of fructose exacerbates liver fibrosis and hepatocarcinogenesis via increased intestinal permeability in a rat steatohepatitis model. <i>Oncotarget</i> , 2018, 9, 28638-28651.	0.8	18
27	Exogenous Administration of Low-Dose Lipopolysaccharide Potentiates Liver Fibrosis in a Choline-Deficient L-Amino-Acid-Defined Diet-Induced Murine Steatohepatitis Model. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2724.	1.8	18
28	Bile Acid Sequestrant, Sevelamer Ameliorates Hepatic Fibrosis with Reduced Overload of Endogenous Lipopolysaccharide in Experimental Nonalcoholic Steatohepatitis. <i>Microorganisms</i> , 2020, 8, 925.	1.6	18
29	Predisposing factors for hepatocellular carcinoma recurrence following initial remission after transcatheter arterial chemoembolization. <i>Oncology Letters</i> , 2017, 14, 3028-3034.	0.8	16
30	TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats. <i>Cells</i> , 2019, 8, 1153.	1.8	16
31	Efficacy of Underwater Endoscopic Mucosal Resection for Superficial Non-Ampullary Duodenal Epithelial Tumor. <i>Clinical Endoscopy</i> , 2021, 54, 371-378.	0.6	16
32	Intestinal Permeability Is a Mechanical Rheostat in the Pathogenesis of Liver Cirrhosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6921.	1.8	16
33	Liver fibrosis progression predicts survival in patients with primary biliary cirrhosis. <i>Hepatology Research</i> , 2017, 47, E178-E186.	1.8	14
34	Serum angiotensin-converting enzyme level for evaluating significant fibrosis in chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2017, 23, 6705-6714.	1.4	14
35	The Angiotensin II Receptor Blocker Losartan Sensitizes Human Liver Cancer Cells to Lenvatinib-Mediated Cytostatic and Angiostatic Effects. <i>Cells</i> , 2021, 10, 575.	1.8	13
36	Efficacy of bi-monthly hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 741-749.	0.6	12

#	ARTICLE	IF	CITATIONS
37	Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2164.	1.8	12
38	Comparison of serum fibrosis biomarkers for diagnosing significant liver fibrosis in patients with chronic hepatitis B. <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 985-995.	0.8	12
39	Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis. <i>Hepatology Communications</i> , 2017, 1, 928-945.	2.0	11
40	Association between Non-Alcoholic Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1635.	1.0	11
41	Lenvatinib prevents liver fibrosis by inhibiting hepatic stellate cell activation and sinusoidal capillarization in experimental liver fibrosis. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 4001-4013.	1.6	11
42	Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 381-389.	4.5	11
43	Association between ADAMTS13 activity and VWF antigen imbalance and the therapeutic effect of HAIC in patients with hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2020, 26, 7232-7241.	1.4	11
44	Periostin cross-reacts with the renin-angiotensin system during liver fibrosis development. <i>Molecular Medicine Reports</i> , 2017, 16, 5752-5758.	1.1	10
45	Platelet hyperaggregability is associated with decreased ADAMTS13 activity and enhanced endotoxemia in patients with acute cholangitis. <i>Hepatology Research</i> , 2018, 48, E52-E60.	1.8	10
46	Glycogenic Hepatopathy in Type 1 Diabetes Mellitus. <i>Internal Medicine</i> , 2018, 57, 1087-1092.	0.3	10
47	Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7588.	1.8	10
48	The association between sarcopenia and endotoxin in patients with alcoholic cirrhosis. <i>Medicine (United States)</i> , 2021, 100, e27212.	0.4	10
49	Novel oral plasminogen activator inhibitor-1 inhibitor TM5275 attenuates hepatic fibrosis under metabolic syndrome via suppression of activated hepatic stellate cells in rats. <i>Molecular Medicine Reports</i> , 2020, 22, 2948-2956.	1.1	10
50	Dual therapy with zinc acetate and rifaximin prevents from ethanol-induced liver fibrosis by maintaining intestinal barrier integrity. <i>World Journal of Gastroenterology</i> , 2021, 27, 8323-8342.	1.4	10
51	Severe Aplastic Anemia following Parvovirus B19-Associated Acute Hepatitis. <i>Case Reports in Hepatology</i> , 2017, 2017, 1-5.	0.4	9
52	Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosis. <i>Hepatology Research</i> , 2019, 49, 1147-1161.	1.8	9
53	Identification of clinical risk factors for histological progression of primary biliary cholangitis. <i>Hepatology Research</i> , 2019, 49, 1015-1025.	1.8	9
54	Proton pump inhibitor therapy does not increase serum endotoxin activity in patients with cirrhosis. <i>Hepatology Research</i> , 2019, 49, 232-238.	1.8	9

#	ARTICLE	IF	CITATIONS
55	Chronic Alcohol Consumption is Inversely Associated with Insulin Resistance and Fatty Liver in Japanese Males. <i>Nutrients</i> , 2020, 12, 1036.	1.7	9
56	Increased Endotoxin Activity Is Associated with the Risk of Developing Acute-on-Chronic Liver Failure. <i>Journal of Clinical Medicine</i> , 2020, 9, 1467.	1.0	8
57	ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 424-435.	0.8	8
58	ADAMTS13, VWF, and Endotoxin Are Interrelated and Associated with the Severity of Liver Cirrhosis via Hypercoagulability. <i>Journal of Clinical Medicine</i> , 2022, 11, 1835.	1.0	8
59	Accuracy of Fibrosis-4 Index in Identification of Patients with Cirrhosis Who Could Potentially Avoid Variceal Screening Endoscopy. <i>Journal of Clinical Medicine</i> , 2020, 9, 3510.	1.0	7
60	Effect of L-carnitine on health-related quality of life in patients with liver cirrhosis. <i>Biomedical Reports</i> , 2020, 13, 1-1.	0.9	7
61	Ratio of von Willebrand factor antigen to ADAMTS13 activity is a useful biomarker for acute-on-chronic liver failure development and prognosis in patients with liver cirrhosis. <i>Hepatology Research</i> , 2022, 52, 390-400.	1.8	7
62	Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet-induced rat steatohepatitis. <i>Digestive and Liver Disease</i> , 2022, 54, 1392-1402.	0.4	7
63	Effect of furosemide on muscle cramps in patients with liver cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 76-81.	1.4	6
64	Association between serum albumin and cognitive dysfunction in hepatic encephalopathy: An exploratory data analysis. <i>JGH Open</i> , 2021, 5, 207-212.	0.7	6
65	Zinc Administration and Improved Serum Markers of Hepatic Fibrosis in Patients with Autoimmune Hepatitis. <i>Journal of Clinical Medicine</i> , 2021, 10, 2465.	1.0	6
66	DNA methylation of angiotensin II receptor gene in nonalcoholic steatohepatitis-related liver fibrosis. <i>World Journal of Hepatology</i> , 2016, 8, 1194.	0.8	6
67	Association between Equol Production Status and Nonalcoholic Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11904.	1.8	6
68	Acyclic retinoid and angiotensin-II receptor blocker exert a combined protective effect against diethylnitrosamine-induced hepatocarcinogenesis in diabetic OLETF rats. <i>BMC Cancer</i> , 2018, 18, 1164.	1.1	5
69	Blocking development of liver fibrosis augments hepatic progenitor cell-derived liver regeneration in a mouse chronic liver injury model. <i>Hepatology Research</i> , 2019, 49, 1034-1045.	1.8	5
70	Effectiveness of Lusutrombopag in Patients with Mild to Moderate Thrombocytopenia. <i>Digestive Diseases</i> , 2020, 38, 329-334.	0.8	5
71	Effect of three or more treatments with lusutrombopag in patients with cirrhotic thrombocytopenia: A retrospective single-center study. <i>Hepatology Research</i> , 2020, 50, 1101-1105.	1.8	5
72	Acylcarnitine: Useful biomarker for early diagnosis of hepatocellular carcinoma in non-steatohepatitis patients. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 887-897.	0.8	5

#	ARTICLE	IF	CITATIONS
73	Angiotensin Receptor Blockers Potentiate the Protective Effect of Branched-Chain Amino Acids on Skeletal Muscle Atrophy in Cirrhotic Rats. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e2100526.	1.5	5
74	Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis. <i>Indian Journal of Gastroenterology</i> , 2022, 41, 169-180.	0.7	5
75	Rifaximin enhances the L-carnitine-mediated preventive effects on skeletal muscle atrophy in cirrhotic rats by modulating the gut-liver-muscle axis. <i>International Journal of Molecular Medicine</i> , 2022, 50, .	1.8	5
76	Efficacy and tolerability of interferon-free regimen for patients with genotype-1 HCV infection. <i>Experimental and Therapeutic Medicine</i> , 2018, 16, 2743-2750.	0.8	4
77	Late-Evening Snack with Branched-Chain Amino Acid-Enriched Nutrients Does Not Always Inhibit Overt Diabetes in Patients with Cirrhosis: A Pilot Study. <i>Nutrients</i> , 2019, 11, 2140.	1.7	4
78	Clinical Significance of Gamma-Glutamyltranspeptidase Combined with Carbohydrate-Deficient Transferrin for the Assessment of Excessive Alcohol Consumption in Patients with Alcoholic Cirrhosis. <i>Medicines (Basel, Switzerland)</i> , 2021, 8, 39.	0.7	4
79	The Combination of Albumin-Bilirubin Score and Prothrombin Time Is a Useful Tool for Predicting Liver Dysfunction after Transcatheter Arterial Chemoembolization in Child-Pugh Class A Patients with Hepatocellular Carcinoma within Up-to-Seven Criteria. <i>Journal of Clinical Medicine</i> , 2021, 10, 4838.	1.0	4
80	Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 65-73.	4.5	4
81	Laser-cut-type versus braided-type covered self-expandable metallic stents for distal biliary obstruction caused by pancreatic carcinoma: a retrospective comparative cohort study. <i>Clinical Endoscopy</i> , 2022, 55, 434-442.	0.6	4
82	Calcified mucinous adenocarcinoma of the stomach metastatic to the iris: a case report. <i>Journal of Medical Case Reports</i> , 2019, 13, 64.	0.4	3
83	Hydralazine Sensitizes to the Antifibrotic Effect of 5-Aza-2'-deoxycytidine in Hepatic Stellate Cells. <i>Biology</i> , 2020, 9, 117.	1.3	2
84	Ascites symptom inventory-7 is a valuable tool for evaluating the effectiveness of tolvaptan in patients with cirrhotic ascites. <i>Experimental and Therapeutic Medicine</i> , 2020, 21, 1-1.	0.8	2
85	Comparison of Ablation Area and Change in Functional Liver Reserve after Radiofrequency Ablation for Hepatocellular Carcinoma Using the arfa® and VIVA® Systems. <i>Journal of Clinical Medicine</i> , 2022, 11, 434.	1.0	2
86	Can portal hypertension and hepatic decompensation be predicted?. <i>Journal of Gastroenterology</i> , 2020, 55, 662-663.	2.3	1
87	Identification of the Response-Related Biomarker of Bimonthly Hepatic Arterial Infusion Chemotherapy. <i>Journal of Clinical Medicine</i> , 2021, 10, 629.	1.0	1
88	Current status of hepatitis test recognition and an attempt of an efficient screening test in an area with a low implementation rate of hepatitis screening. <i>Acta Hepatologica Japonica</i> , 2021, 62, 89-91.	0.0	1
89	Protein-losing gastroenteropathy complicated with asymptomatic primary biliary cholangitis, refractory to immunosuppressant, and improved by <i>Helicobacter pylori</i> eradication: a case report. <i>BMC Gastroenterology</i> , 2022, 22, 101.	0.8	1
90	Therapeutic effect of dual oral therapy with daclatasvir and asunaprevir for chronic HCV patient with depression. <i>Acta Hepatologica Japonica</i> , 2016, 57, 496-498.	0.0	0

#	ARTICLE	IF	CITATIONS
91	VIII. Chronic liver diseases after eradication of viral hepatitis-Clinical landscape of NASH and alcoholic liver disease-. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 57-63.	0.0	0
92	III. Role of Gut Microbiota and Enteral Metabolites in NASH. The Journal of the Japanese Society of Internal Medicine, 2020, 109, 27-33.	0.0	0
93	Ascites symptom inventory-7 is a valuable tool for evaluating the effectiveness of tolvaptan in patients with cirrhotic ascites. Experimental and Therapeutic Medicine, 2021, 21, 30.	0.8	0
94	Endotoxin Activity Reflects an Increase in Body Temperature in Cirrhotic Patients With Ascites Undergoing Cell-free and Concentrated Ascites Reinfusion Therapy. In Vivo, 2022, 36, 1477-1484.	0.6	0